These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


167 related items for PubMed ID: 2687007

  • 1. Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes.
    Heinz G, Komjati M, Korn A, Waldhäusl W.
    Eur J Clin Pharmacol; 1989; 37(1):33-6. PubMed ID: 2687007
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
    Johnston PS, Feig PU, Coniff RF, Krol A, Davidson JA, Haffner SM.
    Diabetes Care; 1998 Mar; 21(3):409-15. PubMed ID: 9540024
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
    Drent ML, Tollefsen AT, van Heusden FH, Hoenderdos EB, Jonker JJ, van der Veen EA.
    Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibition of glycemic and hormonal responses after repetitive sucrose and starch loads by different doses of the alpha-glucosidase inhibitor miglitol (BAY m 1099) in man.
    Lembcke B, Fölsch UR, Gatzemeier W, Ebert R, Siegel E, Creutzfeldt W.
    Pharmacology; 1991 Jun; 43(6):318-28. PubMed ID: 1784628
    [Abstract] [Full Text] [Related]

  • 9. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients.
    Johnston PS, Coniff RF, Hoogwerf BJ, Santiago JV, Pi-Sunyer FX, Krol A.
    Diabetes Care; 1994 Jan; 17(1):20-9. PubMed ID: 8112185
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
    Segal P, Feig PU, Schernthaner G, Ratzmann KP, Rybka J, Petzinna D, Berlin C.
    Diabetes Care; 1997 May; 20(5):687-91. PubMed ID: 9135927
    [Abstract] [Full Text] [Related]

  • 14. Miglitol, a new alpha-glucosidase inhibitor.
    Sels JP, Huijberts MS, Wolffenbuttel BH.
    Expert Opin Pharmacother; 1999 Nov; 1(1):149-56. PubMed ID: 11249557
    [Abstract] [Full Text] [Related]

  • 15. Alpha glucosidase inhibition in the treatment of non-insulin-dependent diabetes mellitus.
    Scott AR, Tattersall RB.
    Diabet Med; 1988 Jan; 5(1):42-6. PubMed ID: 2964327
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Miglitol (BAY m 1099) treatment of diabetic hypothalamic-dietary obese rats improves islet response to glucose.
    Axen KV, Li X, Sclafani A.
    Obes Res; 1999 Jan; 7(1):83-9. PubMed ID: 10023734
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Delayed absorption of carbohydrates in the therapy of Type II diabetes: comparison between dietary (Muesli) and pharmacological (Alpha-glucosidase inhibition) modification].
    Willms B, Lübke D, Ahrens K, Arends J.
    Schweiz Med Wochenschr; 1991 Sep 21; 121(38):1379-82. PubMed ID: 1656521
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.